AU2017235618B2 - Ambrisentan for use in the treatment of acute renal failure - Google Patents
Ambrisentan for use in the treatment of acute renal failure Download PDFInfo
- Publication number
- AU2017235618B2 AU2017235618B2 AU2017235618A AU2017235618A AU2017235618B2 AU 2017235618 B2 AU2017235618 B2 AU 2017235618B2 AU 2017235618 A AU2017235618 A AU 2017235618A AU 2017235618 A AU2017235618 A AU 2017235618A AU 2017235618 B2 AU2017235618 B2 AU 2017235618B2
- Authority
- AU
- Australia
- Prior art keywords
- ambrisentan
- subject
- administered
- renal
- liquid composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662310221P | 2016-03-18 | 2016-03-18 | |
| US62/310,221 | 2016-03-18 | ||
| EP16166046.9 | 2016-04-19 | ||
| EP16166046.9A EP3235496A1 (en) | 2016-04-19 | 2016-04-19 | Treatment of acute renal failure |
| US201662437949P | 2016-12-22 | 2016-12-22 | |
| US62/437,949 | 2016-12-22 | ||
| PCT/EP2017/056476 WO2017158199A1 (en) | 2016-03-18 | 2017-03-20 | Ambrisentan for use in the treatment of acute renal failure |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2017235618A1 AU2017235618A1 (en) | 2018-09-27 |
| AU2017235618B2 true AU2017235618B2 (en) | 2021-02-25 |
Family
ID=55808404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017235618A Active AU2017235618B2 (en) | 2016-03-18 | 2017-03-20 | Ambrisentan for use in the treatment of acute renal failure |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10870021B2 (enExample) |
| EP (3) | EP3235496A1 (enExample) |
| JP (1) | JP7237362B2 (enExample) |
| KR (1) | KR20180121539A (enExample) |
| CN (1) | CN109069443A (enExample) |
| AU (1) | AU2017235618B2 (enExample) |
| BR (1) | BR112018067602A2 (enExample) |
| CA (1) | CA3015432A1 (enExample) |
| CL (1) | CL2018002638A1 (enExample) |
| DK (1) | DK3429566T3 (enExample) |
| ES (2) | ES2856960T3 (enExample) |
| HK (1) | HK1259616A1 (enExample) |
| IL (1) | IL261457B (enExample) |
| MX (1) | MX374534B (enExample) |
| SG (1) | SG11201808009SA (enExample) |
| WO (1) | WO2017158199A1 (enExample) |
| ZA (1) | ZA201805562B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3639827A1 (en) * | 2018-10-19 | 2020-04-22 | Noorik Biopharmaceuticals AG | Use of ambrisentan for the treatment of portal hypertension and cirrhosis |
| EP4142731A1 (en) * | 2020-04-28 | 2023-03-08 | Noorik Biopharmaceuticals AG | Treatment of pulmonary complications of coronavirus infections |
| US20230165856A1 (en) * | 2020-04-29 | 2023-06-01 | Astrazeneca Ab | Dapagliflozin and ambrisentan for the prevention and treatment of covid-19 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110319333A1 (en) * | 2010-06-24 | 2011-12-29 | Morehouse School Of Medicine | Method and compositions for the treatment and detection of endothelin-1 related kidney diseases |
| WO2014138738A1 (en) * | 2013-03-08 | 2014-09-12 | Abbive Inc. | Methods of treating acute kidney injury |
| US20150125546A1 (en) * | 2013-11-06 | 2015-05-07 | Gilead Sciences, Inc. | Combination therapy for treating pulmonary hypertension |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19533023B4 (de) | 1994-10-14 | 2007-05-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
| EP2183223A2 (en) * | 2007-07-31 | 2010-05-12 | Gilead Colorado, Inc. | Metabolites and derivatives of ambrisentan |
| AU2013226944B2 (en) | 2012-02-29 | 2017-03-23 | Toray Industries, Inc. | Inhibitory agent for body cavity fluid accumulation |
| JP6522584B2 (ja) | 2013-04-26 | 2019-05-29 | ラ ホヤ ファーマシューティカル カンパニーＬａ Ｊｏｌｌａ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏｍｐａｎｙ | 腎不全を処置するための組成物及び方法 |
-
2016
- 2016-04-19 EP EP16166046.9A patent/EP3235496A1/en not_active Withdrawn
-
2017
- 2017-03-20 EP EP20175547.7A patent/EP3878439B1/en active Active
- 2017-03-20 AU AU2017235618A patent/AU2017235618B2/en active Active
- 2017-03-20 ES ES17711211T patent/ES2856960T3/es active Active
- 2017-03-20 WO PCT/EP2017/056476 patent/WO2017158199A1/en not_active Ceased
- 2017-03-20 EP EP17711211.7A patent/EP3429566B1/en active Active
- 2017-03-20 KR KR1020187026495A patent/KR20180121539A/ko not_active Ceased
- 2017-03-20 CA CA3015432A patent/CA3015432A1/en active Pending
- 2017-03-20 DK DK17711211.7T patent/DK3429566T3/da active
- 2017-03-20 CN CN201780017563.3A patent/CN109069443A/zh active Pending
- 2017-03-20 ES ES20175547T patent/ES2966638T3/es active Active
- 2017-03-20 US US16/084,340 patent/US10870021B2/en active Active
- 2017-03-20 HK HK19101803.4A patent/HK1259616A1/zh unknown
- 2017-03-20 JP JP2019500021A patent/JP7237362B2/ja active Active
- 2017-03-20 MX MX2018011222A patent/MX374534B/es active IP Right Grant
- 2017-03-20 BR BR112018067602A patent/BR112018067602A2/pt not_active Application Discontinuation
- 2017-03-20 SG SG11201808009SA patent/SG11201808009SA/en unknown
-
2018
- 2018-08-21 ZA ZA2018/05562A patent/ZA201805562B/en unknown
- 2018-08-29 IL IL261457A patent/IL261457B/en unknown
- 2018-09-14 CL CL2018002638A patent/CL2018002638A1/es unknown
-
2020
- 2020-10-07 US US17/065,097 patent/US11642307B2/en active Active
-
2023
- 2023-03-31 US US18/129,516 patent/US20230233454A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110319333A1 (en) * | 2010-06-24 | 2011-12-29 | Morehouse School Of Medicine | Method and compositions for the treatment and detection of endothelin-1 related kidney diseases |
| WO2014138738A1 (en) * | 2013-03-08 | 2014-09-12 | Abbive Inc. | Methods of treating acute kidney injury |
| US20150125546A1 (en) * | 2013-11-06 | 2015-05-07 | Gilead Sciences, Inc. | Combination therapy for treating pulmonary hypertension |
Non-Patent Citations (2)
| Title |
|---|
| L ZHANG, "Ambrisentan improves the outcome of rats with liver transplantation partially through reducing nephrotoxicity", EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, (2014-01-01), vol. 18, no. 17, pages 2575 - 2583 * |
| RAINA AMRESH ET AL, TRANSPLANTATION 15 NOV 2012, (2012-11-15), vol. 94, no. 9, ISSN 1534-6080, pages 885 - 893 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US10870021B2 (en) | 2020-12-22 |
| SG11201808009SA (en) | 2018-10-30 |
| IL261457A (en) | 2018-10-31 |
| JP2019515942A (ja) | 2019-06-13 |
| KR20180121539A (ko) | 2018-11-07 |
| EP3429566A1 (en) | 2019-01-23 |
| EP3878439A1 (en) | 2021-09-15 |
| EP3878439B1 (en) | 2023-10-04 |
| CA3015432A1 (en) | 2017-09-21 |
| BR112018067602A2 (pt) | 2019-01-08 |
| MX2018011222A (es) | 2019-01-10 |
| HK1259616A1 (zh) | 2019-12-06 |
| ES2856960T3 (es) | 2021-09-28 |
| US20190083820A1 (en) | 2019-03-21 |
| MX374534B (es) | 2025-03-06 |
| US20230233454A1 (en) | 2023-07-27 |
| EP3429566B1 (en) | 2021-01-27 |
| CN109069443A (zh) | 2018-12-21 |
| US11642307B2 (en) | 2023-05-09 |
| CL2018002638A1 (es) | 2019-01-18 |
| JP7237362B2 (ja) | 2023-03-13 |
| ZA201805562B (en) | 2019-06-26 |
| US20210046332A1 (en) | 2021-02-18 |
| NZ746140A (en) | 2022-03-25 |
| WO2017158199A1 (en) | 2017-09-21 |
| ES2966638T3 (es) | 2024-04-23 |
| EP3235496A1 (en) | 2017-10-25 |
| IL261457B (en) | 2021-09-30 |
| DK3429566T3 (da) | 2021-03-29 |
| AU2017235618A1 (en) | 2018-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230233454A1 (en) | Ambrisentan for use in the treatment of acute renal failure | |
| US9597398B2 (en) | Formulations of bendamustine | |
| Cox et al. | Ethylene glycol toxicity | |
| BRPI0621528A2 (pt) | composição farmacêutica contendo lactato e cálcio, e usos da mesma | |
| NZ746140B2 (en) | Ambrisentan for use in the treatment of acute renal failure | |
| NZ786075A (en) | Ambrisentan for use in the treatment of acute renal failure | |
| US11883400B2 (en) | Treatment of portal hypertension and cirrhosis | |
| Saupe et al. | Effects of AT1 receptor block begun late in life on normal cardiac aging in rats | |
| US20230241218A1 (en) | Formulations of bendamustine | |
| Bland-van den Berg | Investigations into the hemodynamic and metabolic effects of fructose 1, 6 diphosphate and prostacyclin in hypovolemic shock | |
| Proteinuria | Renal Transplant Dysfunction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |